New Market Study Published: Switzerland Pharmaceuticals & Healthcare Report Q1 2011

Fast Market Research recommends "Switzerland Pharmaceuticals & Healthcare Report Q1 2011" from Business Monitor International, now available
 
Dec. 30, 2010 - PRLog -- In BMI's Q111 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.4 out of 100. Switzerland was ranked first of the 10 countries in the region with a composite score of 73.0. In terms of disease burden, Switzerland ranks among the healthiest countries in Western Europe, supporting a recent OECD report and suggests that Switzerland's high levels of healthcare expenditure, along with relatively healthy lifestyles, are keeping the disease burden low. However, BMI anticipates that Switzerland may fall down the world rankings in the medium to long term as Western Europe's attractiveness compared with large, high-growth emerging markets - such as Brazil and China - declines. The attractiveness of Western Europe over the next decade is forecast to decline as governments are forced to implement austerity measures to reduce fiscal deficits, with healthcare expenditure likely to be reduced.

Price cuts were implemented in Switzerland in January 2010, with the aim at creating savings of approximately CHF800mn (US$721mn). These cuts include changes in wholesale margins, reference pricing and realigning the prices of generic medicines. Wholesale margins applied to drug prices have been reduced by 3% for those costing CHF800 (US$721) or more, while the maximum margin has been lowered from 15% to 12%. For medicines that cost CHF800 (US$721) or less, the maximum margin has been lowered to 7%, (from 10%). The basket of countries used to reference drug prices has expanded to include Austria and France, in addition to Germany, Denmark, the UK and the Netherlands. Generic medicines will be priced at 50, 60 or 80% of the price of the originator medicine. The pricing differentials, in particular the 50% section, have been implemented to encourage the use of generic medicines over higher-priced originator drugs.

Switzerland has a long tradition of drug development and accounts for around 5% of global pharmaceutical research and development (R&D). The country's R&D success is partly due to its wellestablished pharmaceuticals industry and the high concentration of technology-based firms, and partly to the more recent emergence of the strong biotechnology sector. The pharmaceutical research sector is characterised by a large number of cooperative deals, with both local and foreign players.

The local industry is dominated by multinationals Novartis and Roche, which collectively account for 60% of domestic production and demonstrate the country's traditional strengths in innovative pharmaceutical development. The country's chemical and pharmaceutical industry contributes about a third of the funds spent annually on research in Switzerland. Since the turn of the century, the Swiss pharmaceutical and chemical industry has consolidated its position in international markets with foreign direct investment (FDI) in more than 80 countries.

The Q3 2010 financial results reported by Novartis and Roche highlight the increasing importance of emerging markets to multinational pharmaceutical companies. Novartis has reported that while pharmaceutical sales growth grew by 5%, sales in Europe dropped by 2% and sales in the US increased by 6%. However, sales in Asia/Africa/Australasia increased 9% and sales in Canada and Latin America were up 18%. Roche reported that sales in the US, Western Europe and Japan contracted due to currency effects and austerity measures, whereas strong demand in Brazil, China, India, Mexico, Russia, South Korea and Turkey drove international markets sales growth up to 11%.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/101660_switzerland_pharmaceuti...


Partial Table of Contents:

CONTENTS
Executive Summary
SWOT Analysis
- Switzerland Pharmaceuticals And Healthcare Industry SWOT
- Switzerland Political SWOT
- Switzerland Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe - Regional Pharmaceutical Business Environment Ratings for Q111
- Rewards
- Risks
Switzerland - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Medicines
- Pricing Regime
- Recent Pricing System Developments
- Reimbursement Regime
Industry Developments
- Epidemiology
- Non-Communicable Disease
- Communicable Disease
- Health Insurance
- Healthcare Sector Financing
- Pharmaceutical Wholesale and Retail Sector
- Research And Development Sector
- Biotechnology Sector
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
- Key Growth Factors - Macroeconomic
- Table: Switzerland - GDP By Expenditure
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2006-2014
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2006-2014
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Recent Company Developments
Company Monitor
- Indigenous Manufacturers
- Novartis
- Roche
- Merck-Serono
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Sanofi-Aventis
- Merck & Co
Country Snapshot: Switzerland Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1016...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Drug, Q210, Dollar, Currency, Us117bn, Pharmaceuticals, Resulting, Q110, Swiss, Austerity
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share